Arcellx Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACLX Nasdaq 8731 https://www.arcellx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcellx Inc

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma - Jan 30th, 2023 2:00 pm
Gilead's (GILD) Application for Trodelvy Gets EMA Validation - Jan 4th, 2023 4:45 pm
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More - Dec 14th, 2022 3:24 pm
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology - Dec 12th, 2022 3:55 pm
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences - Dec 9th, 2022 9:08 pm
Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead - Dec 9th, 2022 2:54 pm
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate - Dec 9th, 2022 2:42 pm
Gilead to co-develop Arcellx's multiple myeloma drug - Dec 9th, 2022 1:46 pm
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress - Dec 9th, 2022 1:17 pm
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma - Dec 9th, 2022 1:17 pm
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma - Dec 9th, 2022 1:15 pm
We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely - Nov 30th, 2022 4:08 pm
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress - Nov 14th, 2022 9:00 pm
‘The bear market rally has more room to run,’ Guggenheim says. Here are 2 stocks to bet on - Nov 14th, 2022 6:13 pm
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock - Oct 27th, 2022 6:37 pm
Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet - Sep 8th, 2022 1:55 pm
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results - Aug 15th, 2022 8:00 pm
Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel - Jun 21st, 2022 8:05 pm
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares - Jun 21st, 2022 8:01 pm
Arcellx Announces Upsizing and Pricing of Follow-On Public Offering - Jun 16th, 2022 2:47 am